← Eichor
Study identifier: NCT07058883 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

Condition: Acne Scars  ·  Sponsor: Nordberg Medical AB

PhaseNA
Planned participants55
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the effectiveness and safety of Juläine, an injectable medical device made of polylactic acid, for treating facial acne scars. Participants with atrophic acne scars will be randomly assigned to receive either Juläine or a placebo (saline). The treatment will consist of three injection sessions over two months, followed by a 12-month observation period. The study will measure changes in scar severity and skin quality over time using clinical assessments and imaging tools. The study is being conducted at multiple dermatology clinics in Poland and is approved by a local ethics committee.

This description comes directly from the study's public registry record.

Talk to the study team

Paweł Kubik, MD, PhD  ·  +48 515 151 388  ·  pawel.kubik@k-lab.com.pl

Always discuss trial participation with your own doctor first.

Locations (2)

Individual Specialist Medical Practice Maria Luiza-PiesiakówGdansk, PolandRecruiting
Centrum Medyczne dr KubikGdynia, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07058883